InMed Pharmaceuticals Inc. (INM) Social Stream
Featured Post From StockTwits About INM
$INM InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that Eric. A. Adams, President and CEO, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical Research & Development, will present at H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021.jheerdink, published August 12, 2021
Mr. Adams and Dr. Hsu will provide an overview of InMed’s ocular program including INM-088, a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (“API”) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.